Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Inogen Inc (INGN) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Top 35% of 5184 stocks scored
Rank correlation · 90D 32.0% Spearman, 357 dates
Market Cap $166M small-cap · #12 of 27 peers
Summary

Inogen Inc (INGN) stock forecast summary

Our AI ranks Inogen Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Inogen Inc is a small-cap company with a market capitalization of $166M. It ranks number 12 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.

For INGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, INGN included.

Follow INGN free
Price

INGN price chart and AI forecast

INGN
Cross-section · 2026-10-16

How INGN ranks among 5184 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Inogen Inc (INGN) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.

Valuation & Market

MetricINGNIndustry medianRank
Market Cap $166M $76M 12/27
P/B Ratio 0.95x 2.28x 16/22
EPS $-0.85 – –
Book Value/Share $6.59 – –
Revenue/Share $13.35 – –
FCF/Share $-0.19 – –

Profitability & Margins

MetricINGNIndustry medianRank
ROE -14.1% -25.0% 8/19
ROA -8.6% -12.9% 8/19
ROIC -14.4% -5.7% 13/22
Gross Margin 52.8% 50.2% 10/20
Operating Margin -8.7% -8.7% 11/21
Net Margin -6.9% -14.0% 8/17
EBT Margin -7.1% -19.3% 10/21
Tax Rate 2.8% – –

Financial Health

MetricINGNIndustry medianRank
Current Ratio 2.74x 2.57x 11/25
Quick Ratio 2.34x 1.89x 7/22
D/E Ratio 0.63x 0.71x 14/24
Financial Leverage 1.63x 1.71x 14/24
Interest Coverage 5397.0x -3.4x 1/21
Working Capital $123M $51M 11/25

Cash Flow

MetricINGNIndustry medianRank
Operating Cash Flow -$3M -$690K 14/25
Free Cash Flow -$5M $2M 12/16
Capital Spending -$2M -$2M 9/16
FCF/Sales -1.4% 1.2% 10/16
CapEx/Sales 0.7% 1.3% 12/16

Operational Efficiency

MetricINGNIndustry medianRank
Asset Turnover 1.24x 0.72x 3/18
Receivables Turnover 7.7x 5.6x 6/17
Inventory Turnover 5.8x 2.1x 4/22
Fixed Assets Turnover 11.2x 5.5x 7/19
Days Sales Outstanding 48 days 65 days 12/17
Days Inventory 62 days 171 days 19/22
Payables Period 55 days 55 days 10/19
Cash Conversion Cycle 55 days 140 days 12/15

Income Statement

MetricINGNIndustry medianRank
Total Revenue $354M $110M 7/19
Operating Income -$31M -$6M 22/25
Net Income -$25M -$7M 13/19
R&D Expense $21M $20M 10/22
SG&A Expense $182M $126M 10/22
Cost of Goods Sold $167M $55M 9/22

Dividend & Shareholder Information

MetricINGNIndustry medianRank
Shares Outstanding 27M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$194M68.0% of assets
Cash & Short-term Investments$87M30.6% of assets
Accounts Receivable$46M16.2% of assets
Inventory$29M10.0% of assets
Total Liabilities$111M38.8% of assets
Short-term Debt$46M16.0% of assets
Quarterly Financial Reports

INGN quarterly financials and insider trading

Industry Peers · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Inogen Inc (INGN) industry peers

Companies classified under the same SEC industry code as Inogen Inc (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
INGN Inogen Inc ▲ $166M – 1.0x
ISRG Intuitive Surgical Inc ▼ $150.74B 49.0x 8.3x
STE Steris Plc ▼ $21.71B 28.8x 3.0x
ZBH Zimmer Biomet Holdings, Inc. ▼ $18.12B 18.9x 1.4x
SNN Smith & Nephew Plc ▼ $12.75B 16.7x –
ALGN Align Technology Inc ▶ $10.46B 25.7x 2.5x
MSA Msa Safety Inc ▼ $6.91B 22.2x 4.9x
ESTA Establishment Labs Holdings Inc. ▲ $1.76B – 81.6x
ENOV Enovis Corp ▶ $1.13B – 0.8x
CDRE Cadre Holdings, Inc. ▼ $1.13B 26.9x 3.3x
AVR Anteris Technologies Global Corp. ▶ $590M – 2.4x
SMTI Sanara Medtech Inc. ▼ $305M – 38.4x
LAKE Lakeland Industries Inc ▲ $90M – 0.7x
NTRB Nutriband Inc. ▲ $76M – 14.2x
APT Alpha Pro Tech Ltd ▲ $57M 14.2x 0.9x
COCH Envoy Medical, Inc. ▼ $52M – –
MYO Myomo, Inc. ▲ $48M – 8.2x
MLSS Milestone Scientific Inc. ▲ $29M – 8.4x
LFWD Lifeward Ltd. ▲ $17M – 1.4x
UEEC United Health Products, Inc. ▲ $14M 5.2x –
CUPR Cuprina Holdings (Cayman) Ltd ▶ $13M – –
RGNT Regentis Biomaterials Ltd. ▶ $10M – 2.2x
CLGN Collplant Biotechnologies Ltd ▶ $7M – 1.1x
LGMK Logicmark, Inc. ▲ $1M – 0.1x
BBLG Bone Biologics Corp ▲ $1M – 0.3x
RBOT Vicarious Surgical Inc. ▼ $550K – 0.1x
FEED Envue Medical, Inc. ▼ $340K – –

Where INGN sits on the market map

Industrial Applications and Services · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Explore the map →
News

Inogen Inc (INGN) stock news

Loading...

FAQ

Inogen Inc (INGN) stock forecast FAQ

What is the Inogen Inc (INGN) stock forecast?

Our AI ranks Inogen Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Inogen Inc stock predictions?

For INGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 32.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Inogen Inc forecasts updated?

Inogen Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Inogen Inc's industry peers?

27 issuers in our coverage, INGN included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.